Display options
Cite
Blazquez JL, Benyamine A, Pasero C, et al. New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity. Front Immunol. 2018;9:1601doi: 10.3389/fimmu.2018.01601.
Blazquez, J. L., Benyamine, A., Pasero, C., & Olive, D. (2018). New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity. Frontiers in immunology, 91601. https://doi.org/10.3389/fimmu.2018.01601
Blazquez, Juan-Luis, et al. "New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity." Frontiers in immunology vol. 9 (2018): 1601. doi: https://doi.org/10.3389/fimmu.2018.01601
Blazquez JL, Benyamine A, Pasero C, Olive D. New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity. Front Immunol. 2018 Jul 11;9:1601. doi: 10.3389/fimmu.2018.01601. eCollection 2018. PMID: 30050536; PMCID: PMC6050389.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2018 Jul 11;9:1601. doi: 10.3389/fimmu.2018.01601. eCollection 2018.

New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity.

Frontiers in immunology

Juan-Luis Blazquez, Audrey Benyamine, Christine Pasero, Daniel Olive

Affiliations

  1. INSERM, U1068, Centre de Recherche en Cancérologie de Marseille (CRCM), Immunity & Cancer, Institut Paoli-Calmettes; Aix-Marseille Université UM105, CNRS UMR 7258, Marseille, France.
  2. Aix-Marseille Université (AMU), Médecine Interne Hôpital Nord, Assistance Publique Hôpitaux de Marseille (AP-HM), Marseille, France.
  3. Imcheck Therapeutics, Marseille, France.
  4. Immunomonitoring platform, Institut Paoli-Calmettes, Marseille, France.

PMID: 30050536 PMCID: PMC6050389 DOI: 10.3389/fimmu.2018.01601

Abstract

Recent findings in the immunology field have pointed out the emergent role of butyrophilins/butyrophilin-like molecules (BTN/BTNL in human, Btn/Btnl in mouse) in the modulation of γδ T cells. As long as the field develops exponentially, new relationships between certain γδ T cell subsets, on one hand, and their BTN/BTNL counterparts mainly present on epithelial and tumor cells, on the other, are described in the scientific literature. Btnl1/Btnl6 in mice and BTNL3/BTNL8 in humans regulate the homing and maturation of Vγ7+ and Vγ4+ T cells to the gut epithelium. Similarly, Skint-1 has shown to shape the dendritic epidermal T cells repertoire and their activation levels in mice. We and others have identified BTN3A proteins are the key mediators of phosphoantigen sensing by human Vγ9Vδ2 T cells. Here, we first synthesize the modulation of specific γδ T cell subsets by related BTN/BTNL molecules, in human and mice. Then, we focus on the role of BTN3A in the activation of Vγ9Vδ2 T cells, and we highlight the recent advances in the understanding of the expression, regulation, and function of BTN3A in tumor immunity. Hence, recent studies demonstrated that several signals induced by cancer cells or their microenvironment can regulate the expression of BTN3A. Moreover, antibodies targeting BTN3A have shown

Keywords: BTN3A; butyrophilins; immunotherapy; tumor immunity; γδ T cells

References

  1. Cell Immunol. 2015 Jul;296(1):31-40 - PubMed
  2. Cell Mol Immunol. 2010 Nov;7(6):409-13 - PubMed
  3. J Invest Dermatol. 2001 Feb;116(2):275-80 - PubMed
  4. J Biol Regul Homeost Agents. 2016 Jan-Mar;30(1):17-30 - PubMed
  5. Nat Immunol. 2014 Jan;15(1):80-7 - PubMed
  6. Eur J Immunol. 2014 Sep;44(9):2571-6 - PubMed
  7. Blood. 2012 Sep 13;120(11):2269-79 - PubMed
  8. J Immunol. 1995 Feb 1;154(3):998-1006 - PubMed
  9. J Exp Med. 1989 Nov 1;170(5):1569-81 - PubMed
  10. Clin Cancer Res. 2011 Apr 1;17(7):1915-23 - PubMed
  11. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3330-5 - PubMed
  12. Cancer Res. 2011 Jul 1;71(13):4562-72 - PubMed
  13. Eur J Immunol. 2013 May;43(5):1274-85 - PubMed
  14. Cancers (Basel). 2016 Nov 24;8(12): - PubMed
  15. Annu Rev Immunol. 2014;32:121-55 - PubMed
  16. Eur J Immunol. 2017 Jun;47(6):982-992 - PubMed
  17. Oncoimmunology. 2017 Jan 6;6(3):e1278099 - PubMed
  18. Oncoimmunology. 2017 Sep 21;7(1):e1372080 - PubMed
  19. J Immunol. 2010 Nov 15;185(10):5907-14 - PubMed
  20. Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10385-10390 - PubMed
  21. J Immunol. 1995 Jun 1;154(11):5986-94 - PubMed
  22. Cell Rep. 2016 May 31;15(9):1973-85 - PubMed
  23. Front Immunol. 2016 Jan 19;7:1 - PubMed
  24. Front Immunol. 2015 Jun 11;6:302 - PubMed
  25. Immunol Rev. 1995 Dec;148:5-18 - PubMed
  26. Cancer Sci. 2013 May;104(5):536-42 - PubMed
  27. J Exp Med. 1989 Apr 1;169(4):1277-94 - PubMed
  28. J Leukoc Biol. 2015 Feb;97(2):259-71 - PubMed
  29. Nat Immunol. 2013 Sep;14(9):908-16 - PubMed
  30. Int J Biol Sci. 2014 Jan 10;10(2):119-35 - PubMed
  31. J Leukoc Biol. 2010 Oct;88(4):757-67 - PubMed
  32. J Immunol. 2008 Mar 15;180(6):3815-23 - PubMed
  33. Nat Immunol. 2012 Feb 12;13(3):272-82 - PubMed
  34. Genomics. 2001 Feb 1;71(3):351-62 - PubMed
  35. PLoS One. 2012;7(6):e38541 - PubMed
  36. J Immunol. 2015 Mar 1;194(5):2390-8 - PubMed
  37. Immunity. 2016 Nov 15;45(5):1148-1161 - PubMed
  38. PLoS One. 2013 Oct 23;8(10):e76965 - PubMed
  39. J Immunol. 2006 Jun 15;176(12):7354-60 - PubMed
  40. Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7311-E7320 - PubMed
  41. Cell Mol Life Sci. 2011 Jul;68(14):2399-408 - PubMed
  42. J Exp Med. 1990 May 1;171(5):1597-612 - PubMed
  43. Front Immunol. 2017 Jun 30;8:761 - PubMed
  44. Psychiatr Clin North Am. 2010 Mar;33(1):35-66 - PubMed
  45. Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4376-81 - PubMed
  46. Immun Inflamm Dis. 2016 Apr 01;4(2):191-200 - PubMed
  47. J Immunol. 2012 Apr 1;188(7):2972-6 - PubMed
  48. J Immunol. 2003 Apr 1;170(7):3696-706 - PubMed
  49. Nat Immunol. 2006 Aug;7(8):843-50 - PubMed
  50. Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14390-14395 - PubMed
  51. Int J Cancer. 2006 Nov 15;119(10):2359-65 - PubMed
  52. Gastroenterology. 2017 Jun;152(8):2011-2021 - PubMed
  53. Immunol Rev. 1991 Apr;120:137-83 - PubMed
  54. J Immunol. 2007 Sep 15;179(6):3804-11 - PubMed
  55. Int Immunol. 1997 Aug;9(8):1065-72 - PubMed
  56. Immunity. 2014 Apr 17;40(4):490-500 - PubMed
  57. Cell. 2016 Sep 22;167(1):203-218.e17 - PubMed
  58. J Exp Med. 2004 Aug 2;200(3):367-76 - PubMed
  59. J Exp Med. 2003 Jan 20;197(2):163-8 - PubMed
  60. Nat Med. 2015 Aug;21(8):938-945 - PubMed
  61. Nat Genet. 2008 May;40(5):656-62 - PubMed
  62. Leukemia. 2014 Dec;28(12):2367-75 - PubMed
  63. Genes Immun. 2009 Jun;10(4):323-33 - PubMed
  64. Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1039-1044 - PubMed
  65. J Immunother. 2012 Oct;35(8):598-606 - PubMed
  66. J Immunol. 2008 Nov 15;181(10):7131-7 - PubMed
  67. Immunity. 2011 Jul 22;35(1):59-68 - PubMed
  68. Oncotarget. 2010 Sep;1(5):329-38 - PubMed
  69. Clin Cancer Res. 2017 Jul 1;23(13):3453-3460 - PubMed
  70. Immunity. 2000 Sep;13(3):303-12 - PubMed
  71. J Immunol. 2011 Jun 1;186(11):6091-5 - PubMed
  72. J Biol Chem. 2012 Sep 21;287(39):32780-90 - PubMed
  73. J Immunol. 1998 Jul 1;161(1):286-93 - PubMed
  74. Eur J Immunol. 2004 Aug;34(8):2089-99 - PubMed
  75. Nature. 1990 Feb 22;343(6260):754-7 - PubMed
  76. Mol Immunol. 2010 Nov-Dec;48(1-3):109-18 - PubMed
  77. Immunity. 2011 Oct 28;35(4):596-610 - PubMed
  78. Bipolar Disord. 2014 Dec;16(8):790-9 - PubMed
  79. J Immunol. 2007 Feb 1;178(3):1523-33 - PubMed
  80. Annu Rev Immunol. 2016 May 20;34:151-72 - PubMed
  81. Immunology. 2008 Apr;123(4):538-46 - PubMed
  82. J Med Chem. 2008 Mar 27;51(6):1747-54 - PubMed
  83. Oncoimmunology. 2016 Apr 25;5(10):e1146843 - PubMed
  84. Eur J Immunol. 2011 Dec;41(12):3443-54 - PubMed
  85. Oncotarget. 2015 Dec 1;6(38):41228-36 - PubMed
  86. Nat Rev Immunol. 2010 Jul;10(7):467-78 - PubMed
  87. Annu Rev Immunol. 2000;18:975-1026 - PubMed
  88. Front Immunol. 2014 Dec 08;5:622 - PubMed
  89. PLoS One. 2010 Jan 27;5(1):e8884 - PubMed
  90. Immunogenetics. 2014 Apr;66(4):243-54 - PubMed
  91. J Immunol Res. 2014;2014:241246 - PubMed

Publication Types